Search Results for "Elisa For Avastin"
Original Source: An Enzyme-Linked Immunosorbent Assay to Study Bevacizumab Pharmacokinetics.
INTRODUCTION:: Bevacizumab is an antivascular endothelial growth factor humanized monoclonal antibody used to inhibit angiogenesis in cancer. It displays an important interindividual pharmacokinetic variability, which could explain part of the interindividual differences in clinical response. Therefore, an assay to measure bevacizumab serum concentrations is needed. METHODS:: An enzyme-linked immunosorbent assay was developed using microtiter plates sensitised with vascular endothelial growth factor165, a r...
Matching Channels
Top 50 Biopharma Products 2011
Ronald A. Rader, president of the Biotechnology Information Institute provided Contract Pharma a list of the Top 57 Biopharma Products by 2011 revenues (in millions). Mr. Rader subscribes to the sam...
Matching News
Avastin unraveled by stratification study, Roche seeks validation
Reanalysis of Avastin registration trial brings Roche strategy for making universal Avastin use in oncology into question again. Study suggests less than half of Avastin treated colorectal cancer pat...
ASCO: continued Avastin after progression increases overall survival in colon cancer
In metastatic colorectal cancer patients who had a follow-up round of second-line Roche/Genentech’s Avastin (bevacizumab) after their disease worsened following initial Avastin plus first-line c...
Avastin Wins FDA Approval For Colorectal Cancer Treatment
The U.S. Food and Drug Administration (FDA) has approved use of Roche's Avastin for patients with colorectal cancer that has gotten worse despite treatment with the medication. This new approval will...
Roche's Avastin Approved For Colon Cancer Treatment By FDA
The U.S. Food and Drug Administration (FDA) has approved use of Roche's Avastin for patients with colorectal cancer that has gotten worse despite treatment with the medication. This new approval will...
Continued Avastin Extends Survival After First Progression in Advanced Colorectal Cancer
Combined second-line treatment with Avastin® (bevacizumab) and standard chemotherapy extends survival in patients with advanced colorectal cancer who have received first-line combined Avastin treatme...
Lilly's Alimta misses maintenance therapy endpoint in NSCLC
Eli Lilly and Co. (NYSE:LLY) said maintenance therapy with Alimta pemetrexed plus Avastin bevacizumab missed the primary endpoint of improving median overall survival (OS) vs. Avastin alone in the Pha...
New England Compounding Center: the Avastin/Lucentis connection
Long-time readers of the blog are aware of my ongoing fixation on the repackaging of the colorectal cancer drug Avastin for injection into the eye to treat wet age related macular degeneration. Genent...
Rerun: Two views on the Avastin/Lucentis debate
The Health Business Blog is taking a break this week, and re-running some posts from August 2008. If you’d like to comment, please do so on the original post. Regular readers remember last ye...
Matching PubMed Articles
FDA. Once on 'fast track,' avastin now derailed.
Changing End Points in Breast-Cancer Drug Approval - The Avastin Story.
In December 2007, the Oncologic Drugs Advisory Committee (ODAC) of the Food and Drug Administration (FDA) met to discuss the risks and benefits of Genentech's Avastin (bevacizumab) for use in combinat...
Bevacizumab (Avastin) in central retinal vein occlusion.
A mutated soluble neuropilin-2 B domain antagonizes VEGF bioactivity and inhibits tumor progression.
Neuropilins (NRP1 and NRP2) are co-receptors for vascular endothelial growth factor (VEGF) and mediate angiogenesis and tumor progression. VEGF binds to the NRP1 and NRP2 B domains. Previously, it was...
The effect of bevacizumab on colon anastomotic healing in rats.
PURPOSE: The aim of the study was to investigate the effect of angiogenesis inhibition by bevacizumab, a monoclonal anti-vascular endothelial growth factor (VEGF) antibody, on the healing process of c...
